ApconiX

#Advertorial #ApconiX #Central nervous system #Drug discovery #Neuroscience

Mitigating ion channel related CNS liability in novel compounds by predicting SAR

In this paid-for advertorial for the Fall 2026 issue of DDW. The ApconiX team are working towards providing a high throughput service to resolve central nervous system (CNS) liabilities earlier in the drug discovery pipeline. Their recently published study is the first reported method to use structure… Read More

#Exclusive Content

#Animal testing #ApconiX #Assays #FDA #Preclinical development

New podcast explores Sengenics’ i-Ome Discovery Microarrays

The latest sponsored DDW Sitting Down With podcast features Professor Jonathan Blackburn, Chief Scientific Officer of Sengenics, who discusses the advantages of functional protein microarrays, challenges to overcome for biomarker discovery, Sengenics’ new i-Ome Discovery… Read More

#News

Human brain
#Animal testing #ApconiX #Assays #FDA #Preclinical development #Sitting Down With podcast

Podcast: The FDA Modernisation Act 2.0 and seizure liability testing

The latest sponsored DDW Sitting Down With podcast is now available. It features Ruth Roberts and Michael Morton, co-founders of ApconiX, and Dr Kimberly Rockley, ApconiX, who discuss novel alternative methods and the impact of the FDA Modernisation Act 2.0 in relation to seizure liability as well as… Read More

#News

Human brain
#Animal testing #ApconiX #Assays #FDA #Preclinical development

How does the FDA Modernisation Act 2.0 impact seizure liability testing in drug discovery?

The latest sponsored DDW Sitting Down With podcast features Ruth Roberts and Michael Morton, co-founders of ApconiX, and Dr Kimberly Rockley, ApconiX, who discuss novel alternative methods and the impact of the FDA Modernisation Act 2.0 in relation to seizure liability as well as talking about the importance… Read More

#Podcasts

#ApconiX #Biosafety testing #Drug safety #Interview #Podcast #Sitting Down With podcast

What are the benefits of a target safety assessment?

In a DDW Sitting Down With podcast with Lu Rahman, Ruth Roberts and Claire Sadler, ApconiX, discuss the benefits of performing a target safety assessment (TSA) during drug discovery and development when a biological target is going to be acted on by a drug. The… Read More

#Exclusive Content

#ApconiX #Drug safety #Interview

New podcast: Why is a target safety assessment so important?

The latest sponsored DDW Sitting Down With podcast is now live. Professor Ruth Roberts, Co-Founder ApconiX, and Claire Sadler, Project Toxicologist, discuss the benefits of carrying out a target safety assessment (TSA) during drug discovery and development whenever a biological target is going to… Read More

#News

#ApconiX #Drug safety #Interview #Sitting Down With #Sitting Down With podcast

How a target safety assessment supports the drug development process

In the latest sponsored DDW Sitting Down With podcast Professor Ruth Roberts, Co-Founder ApconiX, and Claire Sadler, Project Toxicologist, discuss the benefits of carrying out a target safety assessment (TSA) during drug discovery and development whenever a biological target is going to be modulated. The speakers outline… Read More

#Podcasts

Kim and Bethan Nanion
#ApconiX #Cardiovascular disease #Drug discovery #Podcast #Screening

Podcast: The benefits of early ion channel screening

The latest sponsored DDW Sitting Down With podcast is now available. It features Dr Michael Morton, Director and Co-founder, ApconiX, and Dr Kimberly Rockley of ApconiX, who discuss the benefits of early ion channel screening. The podcast covers the hERG ion channel and its importance in cardiac safety screening… Read More

#News

Kim and Bethan Nanion
#ApconiX #Cardiovascular disease #Drug discovery #Podcast #Screening

The benefits of early ion channel screening

The latest sponsored DDW Sitting Down With podcast features Dr Michael Morton, Director and Co-founder, ApconiX, and Dr Kimberly Rockley of ApconiX who discuss the benefits of early ion channel screening. The podcast covers the hERG ion channel and its importance in cardiac safety screening in drug discovery. … Read More

#News